State-of-the-Art Care for HER2+ Metastatic Breast Cancer
Systemic treatment options available for HER2+ metastatic breast cancer based on recent clinical trial data and abstract presentations from the ASCO 2021 virtual meeting.
Advertisement
State-of-the-Art Care for HER2+ Metastatic Breast Cancer
The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.
Considerations for initiating trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received previous treatment with trastuzumab emtansine based on data demonstrated by the DESTINY-Breast01 study.
Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.
Best practices for preventing and managing treatment-related adverse events associated with systemic therapies used to treat HER2-positive metastatic breast cancer.
Breast oncologists discuss the pros and cons of treating patients with HER2-postive breast cancer with the fixed-dose subcutaneous formulation of pertuzumab plus trastuzumab compared with IV chemotherapy.
Variables that breast oncologists need to consider when selecting an appropriate systemic treatment approach for a patient with HER2-positive breast cancer.
Recommendations for screening patients with HER2-positive metastatic breast cancer for signs of brain metastasis as a consequence of current rates of prevalence.
Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.
Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.
Vijayakrishna Gadi, MD, PhD, defines triple-positive breast cancer and reacts to the potential use of trastuzumab combined with endocrine therapy as frontline therapy.
An overview of various trials investigating combination approaches as frontline therapy for triple-positive breast cancer and considerations for when to use chemotherapy and bring endocrine therapy into treatment.
Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.
